Side by side
Consultation participation and their own register declarations, side by side. Counts, not judgments — participation is not influence.
Counts here are a floor, never a total: they cover the 583 consultation files tracked so far (42,224 submissions, mostly 2025–26), so an organization's real filing history is larger, not smaller.
Industry association · United States
Industry association · Italy
Declared costs: €900K+ a year · in the register since 2009
Compulsory licensing of patents in crisis situations · Supplementary protection certificate for plant protection products. Recast
Register facts self-declared (snapshot 2 Sept 2026); cost bands are floors. Shared files are shared attention, not evidence of coordination.
Their opening passages on the files they share, verbatim and in filing order. We do not summarize, compare, or characterize positions — read them at source.
Pharmaceutical Research and Manufacturers of America · filed 29 Apr 2022 · source
PhRMA, and the innovative biopharmaceutical companies that it represents, has serious concerns with the call for legislative action regarding compulsory licensing in the EU and its Member States. While the call for evidence recognizes that compulsory licensing should be a tool of last resort, it suggests that there is a need for a central compulsory licensing mechanism in Europe for use in a potential crisis.
Confindustria · filed 18 Jul 2023 · source
Confindustria contributed and agrees with BusinessEurope's position paper on European Commission proposal for mandatory authorization for the crisis management. Confindustria, in line with European industry, expresses strong concern about the EC proposal, which risks weakening the European patent law system to the detriment of innovation and competitiveness in the Eurozone
Confindustria · filed 1 Apr 2022 · source
A centralized system for the grant and enforcement of a Unitary SPC (“uSPC”) through a single procedure, analogously with what is being achieved with the European Patent with Unitary Effect and Unified Patent Court ( EP-UE and UPC, respectively) is certainly a very desirable option with a view to creating a more predictable, less burdensome and cost-effective system for Europe.
Pharmaceutical Research and Manufacturers of America · filed 5 Apr 2022 · source
The Pharmaceutical Research and Manufacturers of America, and the innovative biopharmaceuticals companies that they represent, commend the European Commission’s call for the development of a single procedure for the granting of supplementary protection certificates (SPCs) in Europe.
2 organizations on one sheet: every file each filed on, their register declarations, and a working link to each submission. Free: we ask for your name and email, and PolicySpeak may contact you about the product (privacy policy). The per-file record stays downloadable without signing up on each file’s page.